ESR1 and breast cancer: Typically, MYC is amplified in 15% of breast cancers, and associated with resistance to hormone therapy in Luminal A cancers.37 We found MYC amplification in up to 35% of pnSTINGlow ER + breast cancers, a significant enrichment in this subgroup.